AstraZeneca (NYSE:AZN) fell about 5% on Thursday, having plunged as much as 9% earlier in the day, after its closely watched Phase III CARDIO-TTRansform trial failed. At its worst, the…
10
Stocks in Spotlight
View all →-
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) Builds a Merchant Revenue Engine as CIO Fund Scales July 3, 2026 -
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) US$50m Partner Commitment Puts CIO Fund Re-Rate in Focus June 26, 2026 -
Growth Stocks WiseTech Global (ASX:WTC) Why the A$30 Sell-Off Could Be a Long-Term Opportunity June 23, 2026
